by divibasicbldev | Apr 1, 2026 | Press Releases
Fast Track designation is one of the FDA’s expedited programs meant to facilitate development and expedite review of new drugs that have the potential to address an unmet medical need in the treatment of a serious or life-threatening conditionMIAMI, April 01,...
by divibasicbldev | Feb 17, 2026 | Press Releases
– Virtual presentation scheduled for Thursday, February 26, 2026, at 4:00 PM ET — Webcast may be accessed here – MIAMI, Feb. 17, 2026 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the...
by divibasicbldev | Jan 13, 2026 | Press Releases
MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation oral macrocyclic MEK inhibitor for the...
by divibasicbldev | Dec 2, 2025 | Press Releases
Extends cash runway through at least the first half of 2028Led by healthcare-dedicated investors, including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners and Squadron Capital Management MIAMI,...
by divibasicbldev | Nov 28, 2025 | Press Releases
Extends cash runway through at least the first half of 2028Led by Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron Capital Management MIAMI, Nov. 28, 2025 (GLOBE NEWSWIRE) —...
